MAPT and Alzheimer disease: Many studies had supported this hypothesis by finding evidences in AD disease models: Aβ immunotherapy demonstrated a decrease in extracellular SP and intracellular Aβ accumulation and did not mitigate phosphorylated tau pathology in 3XTg-AD (amyloid precursor protein (APP), Presenilin and tau) mice (Oddo et al., 2004).